Life Sciences

GSK’s Jemperli Meets Survival Goal in Endometrial Cancer Trial

GSK’s Jemperli Meets Survival Goal in Endometrial Cance...

Oct 31, 2023

GSK is crowing about a victory for its PD-1 inhibitor Jemperli after it was quic...

Merck invests $169 million for selective PARP1 medication

Merck invests $169 million for selective PARP1 medication

Oct 31, 2023

Merck KGaA is reaffirming its commitment to the burgeoning field of PARP inhibit...

Belgium Considers Short-Term Prohibition of Novo’s Ozempic Weight Loss Drug

Belgium Considers Short-Term Prohibition of Novo’s Ozem...

Oct 27, 2023

Belgium is mulling over a temporary ban on the utilization of Novo Nordisk’s Oze...

AstraZeneca’s Self-Administered Flu Vaccine Inches Closer to FDA Green Light

AstraZeneca’s Self-Administered Flu Vaccine Inches Clos...

Oct 27, 2023

FluMist, AstraZeneca’s nasal spray influenza vaccine, has been on the market for...

EnginZyme Utilizes Biocatalysis to Manufacture Essentia...

Oct 27, 2023

EnginZyme AB, a cutting-edge technology company specializing in enzymatic bioman...

Merck eliminates two preclinical Kelun programs to reduce its ADC pipeline

Merck eliminates two preclinical Kelun programs to redu...

Oct 25, 2023

Merck & Co. has chosen to streamline its portfolio of antibody-drug conjugates (...

Roivant to Sell Gut Disease Drug to Roche in Deal Over $7B

Roivant to Sell Gut Disease Drug to Roche in Deal Over $7B

Oct 25, 2023

Approximately a year ago, pharmaceutical company Roivant Sciences established a ...

Roche invests $7 billion to compete with Merck in the bowel disease market

Roche invests $7 billion to compete with Merck in the b...

Oct 25, 2023

Roche has made a significant $7 billion investment to challenge Merck & Co in th...

Merck & Co. Invests Heavily in Promising Antibody-Drug Conjugates (ADCs)

Merck & Co. Invests Heavily in Promising Antibody-Drug ...

Oct 21, 2023

Merck & Co. is making a bold move in the world of pharmaceuticals, securing a si...

Basilea spends $2 million to acquire clinical-stage antifungal

Basilea spends $2 million to acquire clinical-stage ant...

Oct 21, 2023

Basilea Pharmaceutica is embarking on its second endeavor to bolster its anti-in...

Siemens Healthineers & Qure.ai partnership Aims to Enhance Tuberculosis Diagnosis Using AI

Siemens Healthineers & Qure.ai partnership Aims to Enha...

Oct 21, 2023

Siemens Healthineers, in collaboration with Qure.ai and the Global Fund to Comba...

Nkarta’s Landmark FDA Approval Propels Expansion of Cell Therapy into Lupus Treatment

Nkarta’s Landmark FDA Approval Propels Expansion of Cel...

Oct 19, 2023

Nkarta has achieved a significant milestone by securing FDA approval to broaden ...

Gilead to invest $100 million in Assembly Bio in return for all current and future programs

Gilead to invest $100 million in Assembly Bio in return...

Oct 19, 2023

In a strategic maneuver aimed at revitalizing Assembly Biosciences, a biotech fi...

Novo Nordisk’s Strategic Move to Acquire KBP Biosciences’ Promising Kidney Disease Drug

Novo Nordisk’s Strategic Move to Acquire KBP Bioscience...

Oct 17, 2023

Novo Nordisk, a global pharmaceutical giant renowned for its groundbreaking diab...

Roche’s Fenebrutinib Breakthrough in Multiple Sclerosis Treatment and Blood-Brain Barrier Penetration

Roche’s Fenebrutinib Breakthrough in Multiple Sclerosis...

Oct 17, 2023

In a phase 2 study focused on multiple sclerosis (MS), Roche’s BTK inhibitor, Fe...

Omeros discontinues renal disease phase 3 treatment post interim review failure

Omeros discontinues renal disease phase 3 treatment pos...

Oct 17, 2023

Omeros has discontinued a phase 3 trial involving narsoplimab for kidney disease...

24
25
26
27
28